An open label, balanced, randomized, two-treatment, two-period, two-sequence, single-dose, crossover, bioequivalence study comparing Maribavir Tablets 200 mg, manufactured by Sun Pharmaceutical Industries Limited, India with LIVTENCITY® (Maribavir) Coated Tablets 200 mg, manufactured by: Catalent CTS, LLC Kansas City, United States of America, packed by: Takeda Ireland Limited Bray, Ireland, imported by: Takeda Pharma Ltda. Highway SP 340 S/N, km 133.5 Jaguariúna Administrative Building -SP CNPJ 60.397.775/0001-74 SAC: 0800 - 7710345, in healthy adult, human subjects under fasting condition.

2025-523487-21-00 Protocol MARIB-04-25 Human pharmacology (Phase I) - Bioequivalence study Ongoing, recruitment ended

Start 5 May 2026 · Status Ongoing, recruitment ended · 1 EU/EEA countries · 1 sites · Protocol MARIB-04-25

Overview

Sponsor-declared trial summary

Phase Human pharmacology (Phase I) - Bioequivalence study
Status Ongoing, recruitment ended
Participants planned 40
Countries 1
Sites 1

cytomegalovirus (CMV) infection and/or disease that is refractory (with or without resistance) to one or more prior therapies in adult patients who have undergone hematopoietic stem cell transplantation (HSCT) or solid organ transplantation (SOT)

Key facts

Sponsor
Sun Pharmaceutical Industries Limited
Participant type
Healthy volunteers
Age range
18-64 years
Gender
Male and Female
Therapeutic area
Diseases [C] - Virus Diseases [C02]
Trial duration
5 May 2026 → ongoing
Decision date (initial)
2026-02-02
Transition trial
No
Low-intervention
No
Rare-disease indication
No
Vulnerable population
Yes

Trial design

CTIS Part I — objectives, methods, condition coding

Conditions and MedDRA coding

cytomegalovirus (CMV) infection and/or disease that is refractory (with or without resistance) to one or more prior therapies in adult patients who have undergone hematopoietic stem cell transplantation (HSCT) or solid organ transplantation (SOT)

Sponsors and contacts

Sponsor organisations, regulatory contacts, third parties

Sun Pharmaceutical Industries Limited

Sponsor organisation
Sun Pharmaceutical Industries Limited
Address
Sun House, 1 Plot No 201 B, Western Express Highway, Goregaon East Western Express Highway Goregaon East
City
Mumbai
Postcode
400063
Country
India

Scientific contact point

Organisation
Sun Pharmaceutical Industries Limited
Contact name
Arshad Khuroo

Public contact point

Organisation
Sun Pharmaceutical Industries Limited
Contact name
Arshad Khuroo

Locations

1 EU/EEA country · 1 investigational sites

By country

CountryMS statusPlanned subjectsSites
Romania Ongoing, recruitment ended 40 1
Rest of world 0

Investigational sites

Romania

1 site · Ongoing, recruitment ended
Terapia S.A.
Clinical Pharmacology and Pharmacokinetics, Strada Fabricii Nr. 124, 400640, Cluj-Napoca

Country notifications

Trial-start, recruitment-start, end and early-termination notifications submitted per Member State

Country Trial startTrial end Recruitment startRecruitment end Early termination
Romania 2026-05-05 2026-05-06 2026-05-14

Application history

2 submissions — initial application plus substantial / non-substantial modifications

#TypeCodeSubmittedReference MSConclusionDecision date
1 INITIAL IN 2025-10-14 Romania Acceptable
2025-12-09
2026-02-02
2 NON SUBSTANTIAL MODIFICATION NSM-1 2026-05-06 Romania Acceptable
2025-12-09
2026-05-06